Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

HEAL-IST IDE Trial

← catalyst calendar

NCT05280093 · readout ≤ 193 d

Sponsored by AtriCure, Inc. (industry) · ATRC — their whole pipeline →.

Phase
Not applicable
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
142estimated
Sites
27
Countries
Belgium, Italy, Netherlands +3

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2022-05-31actualWhen the study began enrolling
Primary completionFeb 2027estimatedThe date the last participant is measured for the primary outcome — the readout window
Study completionFeb 2028estimatedThe whole study's end, after follow-up
First posted2022-03-15actualWhen this record first appeared on the registry
Results postedWhen the sponsor posted results to the registry
Record updated2026-03-02actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

  • Inappropriate Sinus Tachycardia

Intervention

  • Device: AtriCure ISOLATOR Synergy Surgical Ablation System

Primary outcomes

what the primary-completion date above is the date OF
Primary Effectiveness Endpoint
measured 12-months Post Procedure
Primary Safety Endpoint
measured 30-days Post Procedure

Publications

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · ATRC's whole pipeline · Catalyst calendar · Every registered study · What changed